Health Care & Life Sciences » Biotechnology | DiaMedica Inc.

DiaMedica Inc. | Income Statement

Fiscal year is January-December. All values CAD Thousands.
2013
2014
2015
2016
2017
Cost of Goods Sold (COGS) incl. D&A
1,179.20
2.90
5.70
2.90
4.60
Gross Income
1,179.20
2.90
5.70
2.90
4.60
SG&A Expense
6,697.50
5,321.80
1,811.40
3,284.80
5,409.70
EBIT
7,876.60
5,324.70
1,817.10
3,287.70
5,414.30
Unusual Expense
31.70
323.10
-
-
121.50
Non Operating Income/Expense
1.70
96.50
108.90
439.30
81.30
Interest Expense
-
4.60
61.00
69.80
6.20
Pretax Income
7,891.00
5,543.60
1,984.50
2,915.90
5,375.30
Income Tax
-
49.10
17.30
29.60
44.50
Consolidated Net Income
7,891.00
5,592.70
2,001.80
2,945.50
5,419.80
Net Income
7,891.00
5,592.70
2,001.80
2,945.50
5,419.80
Net Income After Extraordinaries
7,891.00
5,592.70
2,001.80
2,945.50
5,419.80
Net Income Available to Common
7,891.00
5,592.70
2,001.80
2,945.50
5,419.80
EPS (Basic)
0.14
0.09
0.03
0.03
0.05
Basic Shares Outstanding
54,625.40
60,756.20
72,494.60
94,715.00
118,715.80
EPS (Diluted)
0.14
0.09
0.03
0.03
0.05
Diluted Shares Outstanding
54,625.40
60,756.20
72,494.60
94,715.00
118,715.80
EBITDA
6,697.50
5,321.80
1,811.40
3,284.80
5,409.70
Non-Operating Interest Income
15.70
12.20
2.40
2.30
4.90

About DiaMedica

View Profile
Address
2 Carlson Parkway North
Minneapolis Minnesota 55447
United States
Employees -
Website http://www.diamedica.com
Updated 09/14/2018
DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. Its products includes DM199 that focused on acute ischemic stroke, and chronic kidney disease; and KLK1 which plays a critical role in the regulation of local blood flow, vasodilation in the body, inflammation, and oxidative stress. The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.